Back to Search
DAVID FARRUGIA, M.D.
M.D.
Internal Medicine Physician
NPI: 1891998563IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Hospitalist Physician
Hospitalist
Code: 208M00000X
257310(NY)
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
257310(NY)
Geriatric Medicine (Internal Medicine) Physician
Internal Medicine — Geriatric Medicine
Code: 207RG0300X
257310(NY)
Education
STATE UNIVERSITY OF NEW YORK AT BUFFALO SCHOOL OF MEDICINE
Class of 2007
Research & Publications (20)
Exploring stigma: medical knowledge and the stigmatisation of parents of children diagnosed with autism spectrum disorder.
PMID 19659737·Sociol Health Illn·2009
8-other
A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer.
PMID 17604939·Eur J Surg Oncol·2008
8-other
Functional assays for classification of BRCA2 variants of uncertain significance.
PMID 18451181·Cancer Res·2008
8-other
Impaired p53 function leads to centrosome amplification, acquired ERalpha phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts.
PMID 18264135·Oncogene·2008
7-preclinical
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
PMID 18264087·Nature·2008
8-other
Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants?
PMID 18036263·Breast Cancer Res·2007
4-observational
Use of electronic pagers to recall patients undergoing outpatient-based chemotherapy.
PMID 16434231·Eur J Oncol Nurs·2006
8-other
Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.
PMID 15695382·Cancer Res·2005
7-preclinical
Genotoxic stress leads to centrosome amplification in breast cancer cell lines that have an inactive G1/S cell cycle checkpoint.
PMID 15064746·Oncogene·2004
8-other
Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
PMID 15150106·Cancer Res·2004
8-other
Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression.
PMID 15331894·Urol Int·2004
8-other
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
PMID 12576452·Clin Cancer Res·2003
3-trial
Reversible life-threatening encephalopathy in the absence of hepatic failure following conventional doses of docetaxel.
PMID 12801056·Clin Oncol (R Coll Radiol)·2003
5-case
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
PMID 11801545·Clin Cancer Res·2002
3-trial
Leucovorin rescue from raltitrexed (tomudex)-induced antiproliferative effects: in vitro cell line and in vivo mouse studies.
PMID 10999757·Clin Cancer Res·2000
7-preclinical
Balb/c mice as a preclinical model for raltitrexed-induced gastrointestinal toxicity.
PMID 10656460·Clin Cancer Res·2000
7-preclinical
Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy.
PMID 10848697·BJU Int·2000
8-other
Potential of intermittent hormone therapy for M+ and M0 prostate cancer patients.
PMID 12497080·Prostate Cancer Prostatic Dis·2000
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1026 UNION RD
WEST SENECA, NY 14224 - Phone
- (716) 628-6996
Quick Facts
- NPI
- 1891998563
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 1
- Years in Practice
- 19
- Publications
- 20
Are you this provider?
Claim Your Profile